Rosuvastatin improves lipid profile in metabolic syndrome
Low-dose rosuvastatin achieves major reductions in LDL-cholesterol and increases HDL-cholesterol in patients with metabolic syndrome, according to results from an AstraZeneca-sponsored study reported at the European
Association for the Study of Diabetes meeting in Munich this week.
The COMETS study randomised 397 patients with metabolic syndrome (a cluster
of three or more cardiovascular risk factors) to treatment with rosuvastatin
(10mg daily), atorvastatin (10mg daily) or placebo for six weeks. The
dose of the statins was then doubled for a further six weeks, and the
placebo group transferred to rosuvastatin (20mg daily).
Results showed that LDL-cholesterol was reduced by 41.7 per cent in the
rosuvastatin group at six weeks, compared with 35.7 per cent in the atorvastatin
group (p<0.001). Levels of HDL-cholesterol increased by 9.3 per cent
after six weeks’ treatment with rosuvastatin, compared with 4.8
per cent with atorvastatin (p<0.001). These differences were maintained
at 12 weeks.
A second study showed similar results in type 2 diabetes. Results after
eight weeks’ treatment showed that 10mg rosuvastatin achieved greater
improvements in the lipid profile than 10mg atorvastatin and similar
effects to a 20mg dose of atorvastatin. |
The
Pharmaceutical Journal
Acrobat
Reader